

Cell Marque™ Tissue Diagnostics


Trilogy® — New Formulation Same Effective Pretreatment

Trilogy® Pretreatment Solution combines deparaffinization, rehydration, and unmasking in one simple step for your IHC testing. Unlike many other options, the Trilogy® pretreatment is gentle on tissue while still possessing the strong unmasking capabilities of a conventional EDTA pretreatment.


As an environmentally-friendly, non-toxic alternative, Trilogy® pretreatment eliminates the need for xylene when working with paraffin-embedded tissue. It encourages standardization of the pretreatment procedure; producing consistent, reliable results.

Deparaffinize.
Rehydrate. Unmask.

3 steps in 1



STAT6
on solitary fibrous Tumor



TTF-1
on lung adenocarcinoma

Ordering Information

| Description | Dilution | Cat. No. |
|----------------|--------------|----------|
| 50 mL of 20X | Concentrated | 922P-04 |
| 200 mL of 20X | Concentrated | 922P-06 |
| 240 mL of 100X | Concentrated | 922P-07 |
| 1 L | Ready-to-Use | 922P-09 |

Disclaimer: Trilogy® belongs to the group of *in vitro* diagnostic (IVD) medical devices and is classified as being Class 1, exempt US FDA, and Health Canada regulation.

To place an order or receive technical assistance

visit www.cellmarque.com
or email service@cellmarque.com

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

Copyright © 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Sigma-Aldrich, Cell Marque and Trilogy are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners.

37940 MS_FL8603EN Ver. 0.0 6/2022

